What is the latest price of Jisandai (Bingtongsha) in 2024?

Epclusa (Epclusa) is an oral antiviral drug developed by Gilead Sciences. It is mainly used to treat chronic hepatitis C (Hepatitis C Virus, HCV) of all genotypes. It contains two active ingredients: Sofosbuvir (Sofosbuvir) and Velpatasvir (Velpatasvir). Sofosbuvir is a nucleotideNS5B polymerase inhibitor that can inhibit the replication of hepatitis C virusRNA. Velpatasvir is an NS5A inhibitor that blocks viral RNA replication and viral particle assembly. The combined effect of the two ingredients can broadly cover the different genotypes of HCV, improving the success rate of treatment and reducing the risk of drug resistance.

Jisandai (Bingtonsha) is now on the market in China and included in the medical insurance catalog. Patients can buy it domestically at a price of about more than 3,000 yuan. For specific prices and medical insurance reimbursement policies, please consult your local hospital or pharmacy. In comparison, the price of generic drugs in India and Bangladesh is relatively low, about a few hundred yuan, and their drug ingredients are basically the same as the domestic versions.

Jisanda (Bingtonsa) is suitable for patients with HCV infection of all genotypes, including those with mild to moderate cirrhosis. For patients with severe cirrhosis (decompensated cirrhosis), the combination of Bingtonsa and Ribavirin can further improve the efficacy. The recommended dosage is one tablet once daily for 12 weeks. Patients should consult their doctor before taking the medication to determine the most appropriate treatment option.

Jisandai (Bingtonsha) has shown a highly effective therapeutic effect in clinical trials, and its cure rate (SVR12, the virus is undetectable 12 weeks after the end of treatment) can reach 95% or more. Common adverse reactions include headache, fatigue, nausea, etc., which are usually mild to moderate. For patients with severe hepatic impairment, their liver function indicators should be closely monitored during medication.

While taking Protonsa, the simultaneous use of proton pump inhibitors and other drugs that may affect the absorption of velpatasvir should be avoided. In addition, patients should receive regular blood tests to monitor treatment progress and adjust medication regimens. Jisandai (Bingtonsha)Not recommended for pregnant and lactating women. Before starting treatment, patients should inform their doctor about all medications they are taking and existing health problems.